Menatetrenone ameliorates reduction in bone mineral density and bone strength in sciatic neurectomized XXXX .

@entity604 @entity170 @entity1555 @entity2331 @entity35 @entity4606
@entity4606 ( @entity4606 ) acts on the bone metabolism. Menatetrenon (MK-4) is a @entity4606 homologue that has been used as a therapeutic agent for @entity170 in Japan. @entity35 models of immobilization induced by sciatic neurectomy are characterized by transiently increased bone resorption and sustained reduction in bone formation. Using such a @entity35 model, we investigated the efficacy of MK-4 on @entity604 . Male @entity35 were subjected to unilateral sciatic neurectomy and administered MK-4 for 28 d beginning day 21 after operation. The effect of MK-4 on the immobilized bone was assessed by measuring the bone mineral density of the femur, breaking force of the femoral diaphysis, and bone histomorphometry in tibial diaphysis. The @entity1555 on both the femoral distal metaphysis and diaphysis was reduced by sciatic neurectomy. The administration of MK-4 ameliorated this reduction in a dose-dependent manner. The administration of 30 mg/kg MK-4 ameliorated the reduction in bone strength. An improvement in bone formation was observed following the administration of MK-4. These results suggest that MK-4 has a therapeutic potential for immobilization-induced @entity2331 .
